HUT71790A - Humanized antibodies reactive with l-selectin - Google Patents

Humanized antibodies reactive with l-selectin Download PDF

Info

Publication number
HUT71790A
HUT71790A HU9501564A HU9501564A HUT71790A HU T71790 A HUT71790 A HU T71790A HU 9501564 A HU9501564 A HU 9501564A HU 9501564 A HU9501564 A HU 9501564A HU T71790 A HUT71790 A HU T71790A
Authority
HU
Hungary
Prior art keywords
immunoglobulin
humanized
human
antibody
selectin
Prior art date
Application number
HU9501564A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9501564D0 (en
Inventor
Man Sung Co
Original Assignee
Protein Design Labs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs filed Critical Protein Design Labs
Publication of HU9501564D0 publication Critical patent/HU9501564D0/hu
Publication of HUT71790A publication Critical patent/HUT71790A/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
HU9501564A 1992-12-01 1993-11-30 Humanized antibodies reactive with l-selectin HUT71790A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98394692A 1992-12-01 1992-12-01

Publications (2)

Publication Number Publication Date
HU9501564D0 HU9501564D0 (en) 1995-07-28
HUT71790A true HUT71790A (en) 1996-02-28

Family

ID=25530200

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9501564A HUT71790A (en) 1992-12-01 1993-11-30 Humanized antibodies reactive with l-selectin

Country Status (12)

Country Link
EP (1) EP0671951A4 (fr)
JP (1) JPH08503617A (fr)
KR (1) KR100371784B1 (fr)
AU (1) AU689090B2 (fr)
CA (1) CA2149025A1 (fr)
CZ (1) CZ140195A3 (fr)
FI (1) FI952658A0 (fr)
HU (1) HUT71790A (fr)
NO (1) NO952160L (fr)
PL (1) PL309249A1 (fr)
RU (1) RU2151612C1 (fr)
WO (1) WO1994012215A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
WO1996040942A1 (fr) * 1995-06-07 1996-12-19 Cytel Corporation Anticorps humanises anti-e-selectine
AU746888B2 (en) * 1995-08-17 2002-05-02 Protein Design Labs, Inc. Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage
CZ45498A3 (cs) * 1995-08-17 1999-01-13 Protein Design Labs, Inc. Použití antiselektinových protilátek pro výrobu farmaceutických kompozic určených pro prevenci mnohačetného selhání orgánů v důsledku vícečetného úrazu a pro prevenci akutního poškození orgánů po aplikaci mimotělního krevního objehu
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
ATE358492T1 (de) * 1996-09-27 2007-04-15 Univ Columbia Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
WO1999043353A2 (fr) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Therapie combinee par anti-selectine et immunodepresseur
US20020029391A1 (en) * 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
EP3689912A1 (fr) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
MX2010006097A (es) 2007-12-05 2010-08-04 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para tratar el prurito.
RU2531521C2 (ru) 2007-12-05 2014-10-20 Чугаи Сейяку Кабусики Кайся Антитело против nr10 и его применение
EP4238993A3 (fr) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène capable de se lier à deux ou plusieurs molécules d'antigène de manière répétée
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
CA2806233C (fr) * 2010-07-26 2021-12-07 Trianni, Inc. Animaux transgeniques et methodes d'utilisation
NZ707327A (en) 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
CA2822610C (fr) * 2010-12-21 2019-09-03 Selexys Pharmaceuticals Corporation Utilisation d'anticorps anti-p-selectine
DK2550363T3 (en) 2011-02-25 2015-03-23 Regeneron Pharma ADAM6 mice
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
MX356429B (es) 2011-12-20 2018-05-29 Regeneron Pharma Ratones con cadena ligera humanizada.
LT3597037T (lt) 2012-06-12 2021-06-10 Regeneron Pharmaceuticals, Inc. Humanizuoti gyvūnai, išskyrus žmones, su apribotu imunoglobulino sunkiosios grandinės lokusu
JP2017510273A (ja) 2014-03-21 2017-04-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 異なる結合特性を示すｖｌ抗原結合タンパク質
KR20210088756A (ko) 2014-03-21 2021-07-14 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
AU2016232715A1 (en) 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
TW202128222A (zh) 2019-11-20 2021-08-01 日商中外製藥股份有限公司 含有抗體之製劑

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions

Also Published As

Publication number Publication date
CA2149025A1 (fr) 1994-06-09
WO1994012215A1 (fr) 1994-06-09
AU5732794A (en) 1994-06-22
JPH08503617A (ja) 1996-04-23
FI952658A (fi) 1995-05-31
NO952160D0 (no) 1995-05-31
KR100371784B1 (ko) 2003-07-22
RU2151612C1 (ru) 2000-06-27
HU9501564D0 (en) 1995-07-28
AU689090B2 (en) 1998-03-26
PL309249A1 (en) 1995-10-02
CZ140195A3 (en) 1996-06-12
EP0671951A1 (fr) 1995-09-20
FI952658A0 (fi) 1995-05-31
NO952160L (no) 1995-07-31
EP0671951A4 (fr) 1997-05-21

Similar Documents

Publication Publication Date Title
AU689090B2 (en) Humanized antibodies reactive with L-selectin
US6210671B1 (en) Humanized antibodies reactive with L-selectin
EP0753065B1 (fr) Anticorps contre la selectine e
US6210670B1 (en) Cross-reacting monoclonal antibodies specific for E-selectin and P-selectin
EP0566647B1 (fr) Immunoglobulines humanisees ameliorees
EP1759709B1 (fr) Anticorps humanisés dirigés contre la molécule d'adhesion leucocytaire VLA-4
US6797492B2 (en) Method for reducing the immunogenicity of antibody variable domains
US8246958B2 (en) Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies
US5665357A (en) Antibodies recognizing tumor associated antigen CA 55.1
JPH04502408A (ja) ＩＬ―２レセプターのｐ５５　Ｔａｃタンパク質に特異的なキメラ免疫グロブリン
BG64651B1 (bg) Рекомбинантни анти-сd4 антитела за терапия в хуманната медицина
SK77393A3 (en) Pharmaceutical mixture for treatment of illnesses by inhibition of intercellular adhesion by elam-1
JP4590734B2 (ja) 抗血栓薬およびヒト化抗フォンビルブランド因子モノクローナル抗体
WO1994012214A1 (fr) Anticorps humanises reagissant avec la cd-18
IE910178A1 (en) Recombinant human anti-CD18 antibodies
AU2869492A (en) Inhibition of vascular narrowing using anti-padgem antibodies
US20020010320A1 (en) Chemeric and humanized antibodies to angiogenin
WO1995015181A1 (fr) Therapie de reperfusin comprenant l'utilisation d'anticorps diriges contre la l-selectine
JP2001510027A (ja) Ｔ細胞活性化および増殖を阻害するＬＯ−ＣＤ２ａ抗体およびその用途